Harmony Biosciences Inc. (HRMY)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States.
Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Country | United States |
IPO Date | Aug 19, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 246 |
CEO | Dr. Jeffrey M. Dayno M.D. |
Contact Details
Address: 630 West Germantown Pike Plymouth Meeting, Pennsylvania United States | |
Website | https://www.harmonybiosciences.com |
Stock Details
Ticker Symbol | HRMY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001802665 |
CUSIP Number | 413197104 |
ISIN Number | US4131971040 |
Employer ID | 82-2279923 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer & Director |
Sandip S. Kapadia CPA, M.B.A. | Executive Vice President, Chief Administrative Officer & Chief Financial Officer |
Andrew Serafin J.D., M.B.A. | Executive Vice President & Chief Strategy Officer |
Brennan Doyle | Vice President & Head of Investor Relations |
Christian Ulrich J.D. | General Counsel & Corporate Secretary |
David Bradshaw | Head of Technical Operations |
Dr. Kumar Budur M.D., M.S. | Executive Vice President and Chief Medical & Scientific Officer |
Jeffrey Dierks M.B.A. | Executive Vice President & Chief Commercial Officer |
Jeffrey S. Aronin | Founder & Non-Executive Chairman |
Tricia Glover | Chief Compliance Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 23, 2025 | 4 | Filing |
Jan 23, 2025 | 4 | Filing |
Jan 21, 2025 | 4 | Filing |
Jan 16, 2025 | 4 | Filing |
Jan 15, 2025 | 4 | Filing |
Jan 13, 2025 | 8-K | Current Report |
Nov 05, 2024 | 4 | Filing |
Nov 05, 2024 | 4 | Filing |
Nov 01, 2024 | 8-K | Current Report |
Oct 31, 2024 | 4 | Filing |